This meta-analysis reviewed data from multiple clinical trials involving 2,897 patients with extensive-stage small-cell lung cancer who had not received prior treatment. The researchers compared adding a PD-1 inhibitor or a PD-L1 inhibitor to platinum-etoposide chemotherapy against using platinum-etoposide alone. The goal was to see if adding these new drugs helped patients live longer and delayed disease progression.
The analysis found that adding either type of inhibitor consistently improved overall survival and progression-free survival compared to chemotherapy alone. There was no statistically detectable difference in survival outcomes between using PD-1 inhibitors and PD-L1 inhibitors. This suggests that both classes of drugs offer similar benefits in this setting.
Safety results showed that serious treatment-related adverse events did not increase when the new drugs were added. However, immune-mediated adverse events were more frequent in the combination groups. The certainty of the findings for survival was high, while certainty for safety was moderate to very low due to some variability in the data. Patients should discuss these trade-offs with their oncology team.
